Sbir phase I: stable prophylactic antibodies

Ended Project Grant Awarded

Award ID
2144054
Recipient
Awarding agency
Obligated
$255,927

Award facts

Assistance listing
47.041 Engineering
Completion date
Place of performance
Cypress, CA 90630, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
The broader impact/commercial potential of this small business innovation research (SBIR) phase I project is to solve a variety of infectious diseases for which there is no adequate prevention or therapy, such as HIV, flu, malaria, and the common cold. Vaccination has proven immensely difficult for these diseases, often because there are countless natural strains. Providing antibodies directly represents a possible solution because some of the broadest antibodies can subdue 97% or more of circulating strains. However, antibodies will not last beyond a few months in the body. This project proposes to make a collection of mutations in the constant part of antibodies to stabilize them potentially for decades or even a lifetime. This will improve public health. This small business innovation research (SBIR) phase I project will advance the potential applications of mutagenizing the FC region of a model antibody toward the eventual development of stable prophylactic antibodies. First, the FC will be made resistant to all cellular and all major microbial antibody proteases. Mutations conferring resistance of antibodies to some proteases have already been achieved; these will be combined in the model system. Resistance to all remaining proteases will be engineered by targeted mutation, if the cleavage sites are known, and by comprehensive mutation, if the cleavage sites are unknown. High-throughput screening of mutants will be facilitated by full-length immunoglobulin G phage display. Second, FC is stabilized in vivo by the neonatal FC receptor (FCRN). An unbiased screen of all possible single and double mutants in FC, also by full-length immunoglobulin G phage display, will isolate mutants that have still further enhanced binding to FCRN. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria.

Quick answers

Who received award 2144054?

2144054 was awarded to Invvax, Inc. by Division of Industrial Innovation (National Science Foundation) on February 18, 2022.

How much is award 2144054 worth?

$255,927 has been obligated on 2144054.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login